{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:09:16Z","timestamp":1774033756529,"version":"3.50.1"},"reference-count":15,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"DOI":"10.1182\/bloodadvances.2025018951","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:51:58Z","timestamp":1769032318000},"page":"1959-1963","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-2512","authenticated-orcid":false,"given":"Laura B.","family":"Oswald","sequence":"first","affiliation":[{"name":"1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-8910","authenticated-orcid":false,"given":"Xiaoyin","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina E.","family":"Ferraris","sequence":"additional","affiliation":[{"name":"2College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabe","family":"De Avila","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Scheiber-Camoretti","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-5921","authenticated-orcid":false,"given":"Lisa M.","family":"Gudenkauf","sequence":"additional","affiliation":[{"name":"4Department of Psychiatry, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-4689","authenticated-orcid":false,"given":"Brent J.","family":"Small","sequence":"additional","affiliation":[{"name":"5School of Nursing, The University of North Carolina at Chapel Hill School of Nursing, Chapel Hill, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5108-5735","authenticated-orcid":false,"given":"Brian D.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-8132","authenticated-orcid":false,"given":"Aasha I.","family":"Hoogland","sequence":"additional","affiliation":[{"name":"1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oanh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvelise","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1430-9810","authenticated-orcid":false,"given":"Sylvia L.","family":"Crowder","sequence":"additional","affiliation":[{"name":"1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-7942","authenticated-orcid":false,"given":"Nathan","family":"Parker","sequence":"additional","affiliation":[{"name":"1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany L.","family":"Carson","sequence":"additional","affiliation":[{"name":"1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine E.","family":"Vinci","sequence":"additional","affiliation":[{"name":"1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-4733","authenticated-orcid":false,"given":"Rachid C.","family":"Baz","sequence":"additional","affiliation":[{"name":"6Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8888","authenticated-orcid":false,"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[{"name":"6Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Blue","sequence":"additional","affiliation":[{"name":"6Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel F.","family":"Grajales-Cruz","sequence":"additional","affiliation":[{"name":"6Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy","family":"Matte","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7808-7490","authenticated-orcid":false,"given":"Brandon","family":"Kale","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4725-1566","authenticated-orcid":false,"given":"David","family":"Kaldas","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-8672","authenticated-orcid":false,"given":"Fabiana","family":"Perna","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda Puglianini","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-4381","authenticated-orcid":false,"given":"Hien","family":"Liu","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-3711","authenticated-orcid":false,"given":"Heather S. L.","family":"Jim","sequence":"additional","affiliation":[{"name":"1Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"3Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren C.","family":"Peres","sequence":"additional","affiliation":[{"name":"7Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"8","key":"2026032014063274100_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2026032014063274100_bib2","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026032014063274100_bib3","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026032014063274100_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026032014063274100_bib5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2026032014063274100_bib6","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\u20132, open-label study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026032014063274100_bib7","unstructured":"US Food and Drug Administration\n          . Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Accessed 27 January 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims."},{"issue":"1","key":"2026032014063274100_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41408-024-01129-0","article-title":"Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel","volume":"14","author":"Banerjee","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026032014063274100_bib9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026032014063274100_bib10","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/cncr.28758","article-title":"Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy","volume":"120","author":"Pearman","year":"2014","journal-title":"Cancer"},{"issue":"5 suppl 1","key":"2026032014063274100_bib11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap Cooperative Group during its first two years","volume":"45","author":"Cella","year":"2007","journal-title":"Med Care"},{"key":"2026032014063274100_bib12","unstructured":"HealthMeasures\n          . PROMIS(R) Score Cut Points. Accessed 11 May 2023. https:\/\/www.healthmeasures.net\/score-and-interpret\/interpret-scores\/promis\/promis-score-cut-points."},{"issue":"1","key":"2026032014063274100_bib13","doi-asserted-by":"crossref","first-page":"17763","DOI":"10.1038\/s41598-025-02720-6","article-title":"Quality of life and symptom burden among hematologic malignancy patients undergoing CAR-T therapy: a cross-sectional study","volume":"15","author":"Dai","year":"2025","journal-title":"Sci Rep"},{"issue":"2","key":"2026032014063274100_bib14","doi-asserted-by":"crossref","first-page":"100007","DOI":"10.1016\/j.bict.2025.100007","article-title":"Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma","volume":"1","author":"Paruzzo","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"issue":"1","key":"2026032014063274100_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/bloodadvances.2023010894","article-title":"Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy","volume":"8","author":"Peres","year":"2024","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/1959\/2508165\/blooda_adv-2025-018951-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/1959\/2508165\/blooda_adv-2025-018951-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:06:39Z","timestamp":1774029999000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/6\/1959\/566168\/Meaningful-change-in-patient-reported-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018951","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,24]]},"published":{"date-parts":[[2026,3,12]]}}}